ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2014
Evaluation of prostate-specific membrane antigen as an imaging reporter.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes.Nature biomedical engineering · 2025Article
- Approaches to Imaging Immune Activation Using PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.Bioactive materials · 2024Article
- PSMA imaging as a non-invasive tool to monitor inducible gene expression in vivo.EJNMMI research · 2024Article
- A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity.Scientific reports · 2022Article
- Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma.Science advances · 2022Article
- Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stabilityNanotheranostics · 2022Article
- Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy.Journal of nanobiotechnology · 2021Article
- Imaging of T-cell Responses in the Context of Cancer Immunotherapy.Cancer immunology research · 2021Review
- A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.Scientific reports · 2021Article
- Review
- Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring.Theranostics · 2021Review
- Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Review
- Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.Molecules (Basel, Switzerland) · 2020Review
- Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- How Non-invasiveFrontiers in physiology · 2020Review
- Molecular Imaging with Reporter Genes: Has Its Promise Been Delivered?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- Imaging of T-cells and their responses during anti-cancer immunotherapy.Theranostics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledGenetic reporters provide a noninvasive method to monitor and evaluate a population of cells. The ideal properties of a gene reporter-probe system include biocompatibility, lack of immunogenicity, low background expression or signal, and high sensitivity of detection. The prostate-specific membrane antigen (PSMA) is an attractive candidate for a genetic reporter as it is a human transmembrane protein with a selective expression pattern, and there are several PSMA imaging agents available for clinical and preclinical applications. We evaluated the use of PSMA as a genetic imaging reporter by comparison to 2 clinically established reporters, the mutant herpes simplex virus type I thymidine kinase and the human sodium-iodide symporter.
methodsAdenoviruses expressing each reporter were constructed and validated in vitro for expression and function. To compare PSMA with existing imaging reporters, a bilateral Matrigel suspension model was established with nude mice bearing cells equally infected with each reporter or control adenovirus. Dynamic PET was performed, and time-activity curves were generated for each reporter-probe pair.
resultsA comparison of peak target-to-background ratios revealed that PSMA offered the highest ratio relative to the control Matrigel suspension as well as muscle. Further, as proof of concept, PSMA was applied as an imaging reporter to monitor adenoviral liver transduction with both nuclear and optical imaging probes.
conclusionThese preliminary studies support further development of PSMA as a noninvasive genetic reporter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.